|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
The present study describes the case of a 48-year-old man who was diagnosed with lung adenocarcinoma with an epidermal growth factor receptor (EGFR) 21 L858R mutation.
|
29552210 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we describe a 54-year-old Chinese man diagnosed with lung adenocarcinoma (cT4N3M1b, stage IV) with neuroendocrine differentiation and L858R mutation on exon 21.
|
28538405 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
All patients were diagnosed with advanced lung adenocarcinoma and harbored EGFR 19del or L858R mutations before treatment.
|
30196239 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
A previously unreported mutation in exon 21 of EGFR, which leads to substitution of alanine for threonine at position 854 (T854A), was identified in one patient with a drug-sensitive EGFR L858R-mutant lung adenocarcinoma after long-term treatment with tyrosine kinase inhibitors.
|
19010870 |
2008 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
A simple and rapid method to detect the epidermal growth factor receptor hot spot mutation L858R in lung adenocarcinoma was developed based on principles similar to the universal heteroduplex generator technology.
|
16931592 |
2006 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our study suggested the intratumoral heterogeneity of EGFR-activating mutations in lung adenocarcinoma confirmed on the single-cell level, which might be associated with EGFR-TKIs response in lung adenocarcinoma patients harboring the EGFR L858R mutation.
|
31014278 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thirty-five LADC patients who received epidermal growth factor receptor (EGFR)-TKI therapy, including ten who received tumor rebiopsy after development of resistance, were subjected to picoliter-ddPCR-cfDNA analysis to determine the fraction of cfDNA with TKI-sensitive (L858R and inflame exon 19 deletions) and -resistant (i.e., T790M) mutations, as well as their concordance with mutation status in rebiopsied tumor tissues.
|
26768482 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Compared with L858R mutation, the genotype of exon 19 deletion had a better survival outcome in terms of PFS and OS in patients with advanced lung adenocarcinoma treated with EGFR-TKIs as second-line therapy after first-line chemotherapy.
|
26041721 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
|
24412618 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Responses to chemotherapy were similar for patients with lung adenocarcinomas with EGFR exon20ins and patients with lung adenocarcinomas with EGFR exon19del/L858R.
|
26096453 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation.
|
25009007 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
The left and right lower lobe lung adenocarcinomas contained EGFR gene mutations: an L858R point mutation in exon 21 in the left lesion and a deletion mutation in exon 19 in the right lesion.
|
30453894 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Herein, we report a case of 2 synchronous lung adenocarcinomas composed of 2 distinct pathological subtypes with different EGFR mutations: homozygous deletion in exon 19 in the papillary subtype of adenocarcinoma and a point mutation of L858R in exon 21 in the tubular adenocarcinoma.
|
18186961 |
2007 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Compared to those with classic activating EGFR mutations, lung adenocarcinomas with exon 20 insertion mutations were characterized by significantly younger age at diagnosis (P = 0.032 for exon 20 insertions vs. L858R) and shorter relapse-free survival [P = 0.045 for exon 20 insertions versus (vs) exon 19 deletions].
|
24419753 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function.
|
29222872 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with advanced lung adenocarcinoma with membranous mutant EGFR (19del or 21 L858R) showed significantly longer progression-free survival than those with cytoplasmic mutant EGFR after gefitinib treatment.
|
31228625 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>EGFR</i> exon 19 deletions and L858R mutation in exon 21 are the most common sensitive mutations in lung adenocarcinoma.
|
31064887 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Intense expression of L858R in the MP component was suggested, and the MP+ patients harboring L858R were at comparatively higher risk of recurrence in the group with pN0M0 lung adenocarcinoma.
|
31732945 |
2020 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expert consensus has defined minimum requirements for routine testing and identification of epidermal growth factor (EGFR) mutations (15% of tumors harbor EGFR exon 19 deletions or exon 21 L858R substitutions) and anaplastic lymphoma kinase (ALK) rearrangements (5% of tumors) in advanced lung adenocarcinomas (ACs).
|
26620497 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our patient supports the proposition that somatic mutation L858R in exon 21 of the EGFR gene accounts for complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
|
16027522 |
2005 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Among 134 postoperative recurrence patients with lung adenocarcinoma harboring EGFR-activating mutation (L858R or exon 19 deletion) treated with EGFR-TKIs, we retrospectively analyzed 61 patients treated with EGFR-TKIs as first-line chemotherapy.
|
23974272 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with the early stage lung adenocarcinoma harboring either 19del or L858R share similar RFS and OS.
|
29026990 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
A 55-year-old female with EGFR mutation (L858R) was diagnosed with lung adenocarcinoma, who was responsive to first-generation EGFR-tyrosine kinase inhibitor (TKI).
|
31382924 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway.
|
22450744 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aimed to identify the discriminating capacity of immunohistochemical (IHC) scoring to detect L858R and E746-A750 deletion mutation in lung adenocarcinoma patients and predict EGFR TKIs response.
|
21858063 |
2011 |